Connect
MJA
MJA

Time to develop guidelines for screening and management of atrial fibrillation in Indigenous Australians

Nicole Lowres and Ben Freedman
Med J Aust 2020; 212 (5): . || doi: 10.5694/mja2.50513
Published online: 16 March 2020

Screening guidelines specific to the needs of Australia's Indigenous population are needed

One‐third of all ischaemic strokes are associated with atrial fibrillation (AF).1 Over the next 15 years, the number of AF‐related strokes in Australia is likely to rise substantially because of the predicted rise in AF prevalence.2 It is conservatively estimated that by 2034 more than 600 000 people in Australia will have AF, but these numbers do not take into account the higher prevalence of AF among Indigenous Australians.2 The prevalence of AF among hospitalised Indigenous patients under 60 years of age was reported by one study to be 2.57%, compared with 1.73% for non‐Indigenous patients.3 These hospital‐specific figures possibly underestimate prevalence, however, as they do not include cases of AF detected in Indigenous medical centres or general practices, or people with undiagnosed AF.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • Heart Research Institute, Charles Perkins Centre, University of Sydney, Sydney, NSW


Correspondence: nicole.lowres@sydney.edu.au

Acknowledgements: 

Nicole Lowres is funded by a NSW Health Early Career Fellowship (H16/52168).

Competing interests:

Ben Freedman has previously received fees and advisory board honoraria from Bayer, Daiichi‐Sankyo, and Pfizer/Bristol‐Myers Squibb, and an honorarium from Omron. Ben Freedman and Nicole Lowres have received investigator‐initiated grants from Pfizer and Bristol‐Myers Squibb.

  • 1. Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014; 45: 2599–2605.
  • 2. Ball J, Thompson DR, Ski CF, et al. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust 2015; 202: 32–35. https://www.mja.com.au/journal/2015/202/1/estimating-current-and-future-prevalence-atrial-fibrillation-australian-adult.
  • 3. Wong CX, Brooks AG, Cheng YH, et al. Atrial fibrillation in Indigenous and non‐Indigenous Australians: a cross‐sectional study. BMJ Open 2014; 4: e006242.
  • 4. Nedkoff L, Kelty EA, Hung J, et al. Stroke risk and cardiovascular mortality for Aboriginal and other Australian patients with atrial fibrillation. Med J Aust 2020; 212: 215–222.
  • 5. Katzenellenbogen JM, Woods JA, Teng TH, Thompson SC. Atrial fibrillation in the Indigenous populations of Australia, Canada, New Zealand, and the United States: a systematic scoping review. BMC Cardiovasc Disord 2015; 15: 87.
  • 6. Poppe K, Rambaldini B, Rolleston A, et al. Atrial fibrillation among indigenous populations globally. Heart Lung Circ 2019; 28 Suppl 2: S39–S40.
  • 7. He VYF, Condon John R, Ralph AP, et al. Long‐term outcomes from acute rheumatic fever and rheumatic heart disease. Circulation 2016; 134: 222–232.
  • 8. Healey JS, Connolly SJ, Gold MR, et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. New Engl J Med 2012; 366: 120–129.
  • 9. NHFA CSANZ Atrial Fibrillation Guideline Working Group; Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018; 27: 1209–1266.
  • 10. Gwynne K, Flaskas Y, Brien C, et al. Opportunistic screening to detect atrial fibrillation in Aboriginal adults in Australia. BMJ Open 2016; 6: e013576.
  • 11. Macniven R, Gwynn J, Fujimoto H, et al. Feasibility and acceptability of opportunistic screening to detect atrial fibrillation in Aboriginal adults. Aust N Z J Public Health 2019; 43: 313–318.
  • 12. Bellinge JW, Paul JJ, Walsh LS, et al. The impact of non‐vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia. Med J Aust 2018; 208: 18–23. https://www.mja.com.au/journal/2018/208/1/impact-non-vitamin-k-antagonist-oral-anticoagulants-noacs-anticoagulation
  • 13. Wong CX, Lee SW, Gan SW, et al. Underuse and overuse of anticoagulation for atrial fibrillation: a study in Indigenous and non‐Indigenous Australians. Int J Cardiol 2015; 191: 20–24.
  • 14. Balabanski AH, Newbury J, Leyden JM, et al. Excess stroke incidence in young Aboriginal people in South Australia: Pooled results from two population‐based studies. Int J Stroke 2018; 13: 811–814.
  • 15. Zhang J, Tang J, Cui X, et al. Indirect comparison of novel oral anticoagulants among Asians with non‐valvular atrial fibrillation in the real world setting: a network meta‐analysis. BMC Cardiovasc Disord 2019; 19: 182.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

More than a refresh required for closing the gap of Indigenous health inequality

Chelsea J Bond and David Singh
Med J Aust 2020; 212 (5): . || doi: 10.5694/mja2.50498
Published online: 16 March 2020

If we are committed to closing the gap, we should be committed to transforming relationships of power between Indigenous and non‐Indigenous people

After over a decade of tabling annual reports of policy failure in Closing the Gap in Indigenous health inequality, the Morrison government announced in 2019 a refresh of the targets, rather than a rethink of the policy approach.1 This refresh includes a process of Indigenous consultation and codesign via the Coalition of the Peaks (a representative body of about 40 Aboriginal and Torres Strait Islander organisations), which makes for a refreshing change in Indigenous health policy.2 Whether such engagement will engender the radical reimagining required to transform persisting Indigenous health disparities remains to be seen.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • University of Queensland, Brisbane, QLD


Correspondence: c.bond3@uq.edu.au

Acknowledgements: 

Chelsea Bond is a recipient of an Australian Research Council Discovery Early Career Research Fellowship.

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Antiplatelet therapy within 30 days of percutaneous coronary intervention with stent implantation

Benjumin Hsu, Michael O Falster, Andrea L Schaffer, Sallie Pearson, Louisa Jorm and David B Brieger
Med J Aust 2020; 213 (3): . || doi: 10.5694/mja2.50507
Published online: 9 March 2020

Percutaneous coronary intervention with stent implantation (PCI‐S) has revolutionised the management of patients with coronary artery disease at high risk of myocardial infarction and stroke.1 Dual antiplatelet therapy (aspirin with clopidogrel, prasugrel or ticagrelor) is superior to aspirin alone for preventing atherothrombotic events, including stent thrombosis, in patients undergoing PCI‐S,2 and is recommended by Australian guidelines.3

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Centre for Big Data Research in Health, UNSW Australia, Sydney, NSW
  • 2 Menzies Centre for Health Policy, University of Sydney, Sydney, NSW
  • 3 Concord Repatriation General Hospital, Sydney, NSW


Correspondence: benjumin.hsu@unsw.edu.au

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Blood lead levels in children have fallen, but vigilance is still needed

Mark P Taylor and Bruce P Lanphear
Med J Aust 2020; 212 (4): . || doi: 10.5694/mja2.50495
Published online: 2 March 2020

Ongoing population‐level strategies are needed to further reduce lead exposure

The largest survey of blood lead levels in children in Australia outside high risk mining and smelting communities since the phasing out of leaded petrol was undertaken as part of the Barwon Infant Study in Victoria. As reported in this issue of the MJA,1 the investigators found that blood lead concentrations in children were considerably lower (geometric mean, 0.95 μg/dL) than those measured in the last major survey of Australian children, more than 25 years ago (geometric mean, 5.05 μg/dL).2 Blood lead levels have declined dramatically over the past 50 years,3,4 and Symeonides and colleagues have found that levels in children continue to fall. Nevertheless, they are still about 60 times higher than in pre‐industrial humans (0.016 μg/dL),5 and health agencies have declared that there is no safe level of lead for children.6,7


  • 1 Macquarie University, Sydney, NSW
  • 2 Simon Fraser University, Burnaby, BC, Canada


Correspondence: mark.taylor@mq.edu.au

Competing interests:

Mark Patrick Taylor is affiliated with the Broken Hill Lead Reference Group, The LEAD Group (Australia), and the Broken Hill Environmental Lead Program of the NSW Environmental Protection Agency (EPA). He has received funding from the Broken Hill Environmental Lead Program for lead‐related research; Australian federal government Citizen Science grants for the project, “Citizen insights to the composition and risks of household dust” (CSG55984); from the Australian Research Council (ARC) for perfluorinated alkylated substances (PFAS)‐related research (SR180100021), an ARC Special Research Initiative Collaboration Agreement; an ARC Linkage grant (with Rio Tinto) for “Improved control of dioxin emissions during iron ore sintering”; and from the Metropolitan Fire Brigade (Victoria) for a clinical trial of PFAS removal from firefighters by phlebotomy. Mark Patrick Taylor has also prepared commissioned reports and provided expert advice on environmental contamination and human health for a range of bodies, including the Australian Building Codes Board (lead in plumbing fittings and materials), lawyers, governments, union agencies, and private companies. He has also received funding from Macquarie University for sabbatical research and major equipment purchases. Bruce Lanphear serves as an expert witness in plaintiff cases of childhood lead poisoning in Milwaukee (WI) and Flint (MI) in the United States, but receives no personal compensation.

  • 1. Symeonides C, Vuillermin P, Sly PD, et al. Pre‐school child blood lead levels in a population‐derived Australian birth cohort: the Barwon Infant Study. Med J Aust 2019; 211: 169–174.
  • 2. Donovan J. Lead in Australian children. Report on the national survey of lead in children. Canberra: Australian Institute of Health and Welfare, 1996. https://www.aihw.gov.au/getmedia/b6d0e6d2-09f1-4ef1-b62b-a0930557509b/lead-in-australian-children.pdf.aspx?inline=true (viewed Aug 2019).
  • 3. Kristensen LJ, Taylor MP, Flegal AR. An odyssey of environmental pollution: the rise, fall and remobilisation of industrial lead in Australia. Applied Geochemistry 2017; 83: 3–13.
  • 4. Robbins N, Zhang Z‐F, Sun J, et al. Childhood lead exposure and uptake in teeth in the Cleveland area during the era of leaded gasoline. Sci Total Environ 2010; 408: 4118–4127.
  • 5. Flegal AR, Smith DR. Lead levels in preindustrial humans. N Engl J Med 1992; 326: 1293–1294.
  • 6. Centers for Disease Control and Prevention. Childhood lead poisoning prevention. July 2019. https://www.cdc.gov/nceh/lead/prevention/default.htm (viewed Nov 2019)
  • 7. World Health Organization. Lead poisoning and health. Aug 2019. https://www.who.int/news-room/fact-sheets/detail/lead-poisoning-and-health (viewed Nov 2019).
  • 8. Canfield RL, Henderson CR, Cory‐Slechta DA, et al. Intellectual impairment in children with blood lead concentrations below 10 μg per deciliter. N Engl J Med 2003; 348: 1517–1526.
  • 9. Budtz‐Jørgensen E, Bellinger D, Lanphear B, et al. An international pooled analysis for obtaining a benchmark dose for environmental lead exposure in children. Risk Anal 2013; 33: 450–461.
  • 10. Reuben A, Schaefer JD, Moffitt TE, et al. Association of childhood lead exposure with adult personality traits and lifelong mental health. JAMA Psychiatry 2019; 76: 418–425.
  • 11. Lanphear BP, Rauch S, Auinger P, et al. Low‐level lead exposure and mortality in US adults: a population‐based cohort study. Lancet Public Health 2018; 3: e177–e184.
  • 12. Reuben A, Caspi A, Belsky DW, et al. Association of childhood blood lead levels with cognitive function and socioeconomic status at age 38 years and with IQ change and socioeconomic mobility between childhood and adulthood. JAMA 2017; 317: 1244–1251.
  • 13. National Toxicology Program. Health effects of low‐level lead (NTP monograph). U.S. Department of Health and Human Services, June 2012. https://ntp.niehs.nih.gov/ntp/ohat/lead/final/monographhealtheffectslowlevellead_newissn_508.pdf (viewed Aug 2019).
  • 14. Lanphear BP. Low‐level toxicity of chemicals: no acceptable levels? PLoS Biol 2017; 15: e2003066.
  • 15. National Health and Medical Research Council. Managing individual exposure to lead in Australia: a guide for health practitioners. Canberra: NHMRC, 2016. https://www.nhmrc.gov.au/about-us/publications/managing-individual-exposure-lead-australia (viewed Nov 2019.
  • 16. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES): blood lead levels in the US population. Updated July 2019. https://www.cdc.gov/nceh/lead/data/nhanes.htm (viewed Aug 2019).
  • 17. Taylor MP, Harvey PJ, Morrison AM. Lead in plumbing products and materials. June 2018. https://www.abcb.gov.au/Resources/Publications/Consultation/Lead-in-Plumbing-Products-and-Materials (viewed Sept 2019).
  • 18. Shaffer RM, Gilbert SG. Reducing occupational lead exposures: strengthened standards for a healthy workforce. NeuroToxicology 2018; 69: 181–186.
  • 19. Safe Work Australia. Lead. Updated July 2019. https://www.safeworkaustralia.gov.au/topic/lead (viewed Aug 2019).
  • 20. Navas‐Acien A, Tellez‐Plaza M, Guallar E, et al. Blood cadmium and lead and chronic kidney disease in US adults: a joint analysis. Am J Epidemiol 2009; 170: 1156–1164.
  • 21. Kamel F, Umbach DM, Hu H, et al. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis 2005; 2: 195–201.
  • 22. Bakulski KM, Rozek LS, Dolinoy DC, et al. Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Curr Alzheimer Res 2012; 9: 563–573.
  • 23. Health Canada. Fourth Report on human biomonitoring of environmental chemicals in Canada. Aug 2017. https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/environmental-contaminants/fourth-report-human-biomonitoring-environmental-chemicals-canada.html (viewed Sept 2019).
  • 24. Nussbaumer‐Streit B, Yeoh B, Griebler U, et al. Household interventions for preventing domestic lead exposure in children. Cochrane Database Syst Rev 2016; CD006047.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Overdiagnosis of cancer in Australia: the role of screening

David M Roder and Elizabeth Buckley
Med J Aust 2020; 212 (4): . || doi: 10.5694/mja2.50494
Published online: 2 March 2020

The balance between benefits and risks could be improved if effective risk‐based screening protocols were developed

Overdiagnosis can be defined as the proportion of diagnosed cancers that would not otherwise have come to a person's attention during their lifetime.1,2 Overdiagnosis provides no benefit to the patient but can have financial, psychosocial, and health consequences.2 While advances in imaging and other screening and diagnostic technologies can lead to therapeutic benefit, they can also increase overdiagnosis. Because overdiagnosed cancers are generally indistinguishable from potentially lethal cancers, the imperative to treat is equivalent.2


  • Cancer Research Institute, University of South Australia, Adelaide, SA


Correspondence: david.roder@unisa.edu.au

Competing interests:

No relevant disclosures.

  • 1. Brodersen J, Schwartz LM, Heneghan C, et al. Overdiagnosis: what is it and what it isn't. BMJ Evid Based Med 2018; 23: 1–3.
  • 2. Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108: 2205–2240.
  • 3. Rainey L, van der Waal D, Jervaeus A, et al. Are we ready for the challenge of implementing risk‐based breast cancer screening and primary prevention? Breast 2018; 39: 24–32.
  • 4. Glasziou PP, Jones MA, Pathirana T, et al. Estimating the magnitude of cancer overdiagnosis in Australia. Med J Aust 2020; 212: 163–168.
  • 5. Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014; 15: e234–e242.
  • 6. Njor SH, Garne JP, Lynge E. Over‐diagnosis estimate from The Independent UK Panel on Breast Cancer Screening is based on unsuitable data. J Med Screen 2013; 20: 104–105.
  • 7. Morrell S, Gregory M, Sexton K, et al. Absence of sustained breast cancer incidence inflation in a national mammography screening programme. J Med Screen 2019; 26: 26–34.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

How to perform a skin biopsy

Kirsty JL Wark, Saxon D Smith and Deshan F Sebaratnam
Med J Aust 2020; 212 (4): . || doi: 10.5694/mja2.50473
Published online: 2 March 2020

The skin has more disease processes than any other organ system in medicine, with over 3000 dermatological conditions described.1 Teaching of dermatology is often neglected in medical training internationally, and most doctors feel ill‐equipped to diagnose cutaneous pathology.2 Compounding this, limitations in access to specialist dermatologists in Australia are well recognised.3 Fortunately, biopsy of the skin is a simple skill to learn which can greatly help with the diagnosis of dermatological diseases. For cutaneous malignancies, the diagnosis is principally based on histopathological findings. However, for rashes, the correlation between clinical and pathological findings is paramount. For instance, observation of a lichenoid reaction pattern on skin biopsy may reflect lichen planus, lupus, dermatomyositis, lichen sclerosus, cutaneous T cell lymphoma, or graft‐versus‐host disease. To maximise the diagnostic yield of a skin biopsy, an understanding of the different types of biopsy, their indications and limitations is vital (Box 1 and Box 2).


  • 1 Liverpool Hospital, Sydney, NSW
  • 2 Royal North Shore Hospital, Sydney, NSW
  • 3 University of Sydney, Sydney, NSW
  • 4 Sydney Children's Hospitals Network, Sydney, NSW


Correspondence: deshan@unsw.edu.au


Series editors

Balakrishnan (Kichu) Nair

Simon O'Connor


Acknowledgements: 

We thank Alicia O'Connor, Anes Yang, Victoria Venning, Imogen Faulds and our patients for their contributions to the clinical images.

Competing interests:

No relevant disclosures.

  • 1. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004: a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490–500.
  • 2. Hussain W, Hafiji J, Stanley AG, Khan KM. Dermatology and junior doctors: an evaluation of education, perceptions and self‐assessed competencies. Br J Dermatol 2008; 159: 505–506.
  • 3. Sebaratnam DF, Murrell DF. Dermatology training and practice in Australia. Int J Dermatol 2014; 53: 1259–1264.
  • 4. de Menezes SL, Kelly JW, Wolfe R, et al. The increasing use of shave biopsy for diagnosing invasive melanoma in Australia. Med J Aust 2019; 211: 213–218. https://www.mja.com.au/journal/2019/211/5/increasing-use-shave-biopsy-diagnosing-invasive-melanoma-australia
  • 5. Elston DM, Stratman EJ, Miller SJ. Skin biopsy: biopsy issues in specific diseases. J Am Acad Dermatol 2016; 74: 1–16.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Hidden in plain sight: umbilical melanoma

Tom Kovitwanichkanont, Shoba Joseph and Leona Yip
Med J Aust 2020; 212 (4): . || doi: 10.5694/mja2.50490
Published online: 2 March 2020

A 74‐year‐old Caucasian woman was referred for hirsutism over the abdomen and was incidentally found to have a 21 × 25 mm ulcerated nodule over the umbilicus (Box 1). This occurred on the background of a longstanding lesion. Over the previous 6 months, the nodule had become ulcerated and occasionally bled. The remainder of the full skin examination was unremarkable, with no concerning lesions or palpable regional lymphadenopathy. She had no previous malignancy but had a strong family history of colorectal, breast, lung and pharyngeal cancer. Results of investigations to exclude internal malignancies were normal. Following an initial incisional biopsy demonstrating malignant amelanotic melanoma, a subsequent wide local excision confirmed this to be a stage IIIC, extensively ulcerated invasive nodular melanoma of 21 mm thickness and Clark level IV, with a mitotic rate of up to 15/mm2. There was no lymphovascular or perineural invasion. Microsatellites, desmoplasia and regression were not identified. The melanoma was BRAF negative on both immunohistochemical and molecular testing. Sentinel lymph node biopsy showed two metastatic melanoma deposits in the left inguinal sentinel node. Initial staging evaluations showed no evidence of nodal or distant metastases on whole body positron emission tomography–computed tomography (PET–CT) and brain magnetic resonance imaging (MRI). The patient was commenced on adjuvant nivolumab immunotherapy, but 4 months into treatment was confirmed by biopsy to have recurrent left inguinal nodal metastatic disease, and a repeat PET–CT scan showed possible in‐transit metastasis in the abdominal wall. Dissection of the involved ilioinguinal lymph node and ultrasound‐guided removal of the abdominal metastatic deposit were being planned at the time of writing.


  • 1 Skin Health Institute, Melbourne, VIC
  • 2 Sinclair Dermatology, Melbourne, VIC
  • 3 Barton Specialist Centre, Canberra, ACT



Acknowledgements: 

We thank Miklos Pohl OAM and Dr Genevieve Bennett for their contributions to patient care.

Competing interests:

No relevant disclosures.

  • 1. Papalas JA, Selim MA. Metastatic vs primary malignant neoplasms affecting the umbilicus: clinicopathologic features of 77 tumors. Ann Diagn Pathol 2011; 15: 237–242.
  • 2. Campos‐Munoz L, Quesada‐Cortes A, Ruiz E, et al. Primary melanoma of the umbilicus appearing as omphalitis. Clin Exp Dermatol 2007; 32: 322–324.
  • 3. Colonna MR, Giovannini UM, Sturniolo G, Colonna U. The umbilicus: a rare site for melanoma. Clinical considerations in two cases. Case reports. Scand J Plast Reconstr Surg Hand Surg 1999; 33: 449–452.
  • 4. Steck WD, Helwig EB. Tumors of the umbilicus. Cancer 1965; 18: 907–915.
  • 5. Mar V, Roberts H, Wolfe R, et al. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2013; 68: 568–575.
  • 6. Gabriele R, Conte M, Egidi F, Borghese M. Umbilical metastases: current viewpoint. World J Surg Oncol 2005; 3: 13.
  • 7. Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Sydney: Cancer Council Australia. 2019. https://wiki.cancer.org.au/australia/Guidelines:Melanoma (viewed Dec 2019).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Misgendering and experiences of stigma in health care settings for transgender people

Irene J Dolan, Penelope Strauss, Sam Winter and Ashleigh Lin
Med J Aust 2020; 212 (4): . || doi: 10.5694/mja2.50497
Published online: 2 March 2020

Misgendering negatively affects the mental and physical health of trans individuals

Misgendering occurs when a person is addressed or described using language that does not match their gender identity.1 Misgendering within the health care system can significantly affect the mental and physical health of transgender (hereafter trans) individuals and can negatively impact future engagement with the health care system. Systemic policies and practices create situations which increase the likelihood of misgendering and experience of stigma, affecting the delivery of health care to trans individuals.


  • 1 HealthPathways WA, Perth, WA
  • 2 Telethon Kids Institute, Perth, WA
  • 3 University of Western Australia, Perth, WA
  • 4 Curtin University, Perth, WA


Correspondence: irene.dolan@wapha.org.au

Acknowledgements: 

Ashleigh Lin is supported by a National Health and Medical Research Council Career Development Fellowship (1148793).

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Bushfire smoke: urgent need for a national health protection strategy

Sotiris Vardoulakis, Bin B Jalaludin, Geoffrey G Morgan, Ivan C Hanigan and Fay H Johnston
Med J Aust 2020; 212 (8): . || doi: 10.5694/mja2.50511
Published online: 24 February 2020

More nuanced health advice is needed to protect populations and individuals from exposure to bushfire smoke

Bushfires have always been a feature of the natural environment in Australia, but the risk has increased over time as fire seasons start earlier, finish later, and extreme fire weather (ie, very hot, dry and windy conditions that make fires fast moving and very difficult to control) becomes more severe with climate change.1,2,3 The 2019–20 bushfires in Australia, particularly in New South Wales, Victoria, Queensland and the Australian Capital Territory, have caused at least 33 fatalities, extensive damage to property and destruction of flora and fauna, and have exposed millions of people to extreme levels of air pollution. Bushfire smoke, as well as smoke from prescribed burns, contains a complex mixture of particles and gases that are chemically transformed in the atmosphere and transported by the wind over long distances.4 In this context, a major public health concern is population exposure to atmospheric particulate matter (PM) with a diameter < 2.5 μm (PM2.5), which can penetrate deep into the respiratory system, inducing oxidative stress and inflammation,5 and even translocate into the bloodstream.6

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, ACT
  • 2 Ingham Institute for Applied Medical Research, University of New South Wales
  • 3 School of Public Health and University Centre for Rural Health, University of Sydney, Sydney, NSW
  • 4 Health Research Institute, University of Canberra, ACT
  • 5 Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS



Acknowledgements: 

This research was undertaken with support from the Australian National University College of Health and Medicine, and the assistance of resources from the Centre for Air pollution, energy and health Research (CAR). We used the CAR Data and Analysis Technology platform (https://cardat.github.io) to analyse data.

Competing interests:

Sotiris Vardoulakis has received funding support from the UK National Institute for Health Research, Medical Research Council, Natural Environment Research Council, Public Health England, EU Horizon 2020, and Dyson Ltd. Geoffrey Morgan and Ivan Hanigan receive funding support from the Australian National Health and Medical Research Council.

  • 1. Harris S, Lucas C. Understanding the variability of Australian fire weather between 1973 and 2017. PLoS One 2019; 14: e0222328.
  • 2. Di Virgilio G, Evans JP, Blake SAP, et al. Climate change increases the potential for extreme wildfires. Geophys Res Lett 2019; 46: 8517–8526.
  • 3. Beggs PJ, Zhang Y, Bambrick H, et al. The 2019 report of the MJA–Lancet Countdown on health and climate change: a turbulent year with mixed progress. Med J Aust 2019; 211: 490–491.e21. https://www.mja.com.au/journal/2019/211/11/2019-report-mja-lancet-countdown-health-and-climate-change-turbulent-year-mixed
  • 4. Johnston FH. Understanding and managing the health impacts of poor air quality from landscape fires. Med J Aust 2017; 207: 229–230. https://www.mja.com.au/journal/2017/207/6/understanding-and-managing-health-impacts-poor-air-quality-landscape-fires.
  • 5. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. J Toxicol 2011; 2011: 487074.
  • 6. Brook RD, Rajagopalan S, Pope CA 3rd, et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 2010; 121: 2331–2378.
  • 7. Morgan G, Sheppeard V, Khalaj B, et al. Effects of bushfire smoke on daily mortality and hospital admissions in Sydney. Australia. Epidemiology 2010; 21: 47–55.
  • 8. Martin KL, Hanigan IC, Morgan GG, et al. Air pollution from bushfires and their association with hospital admissions in Sydney, Newcastle and Wollongong, Australia 1994‐2007. Aust. N Z J Public Health 2013; 37: 238–243.
  • 9. Johnston FH, Purdie S, Jalaludin B, et al. Air pollution events from forest fires and emergency department attendances in Sydney, Australia 1996‐2007: a case‐crossover analysis. Environ Health 2014; 13: 105.
  • 10. Salimi F, Henderson SB, Morgan GG, et al. Ambient particulate matter, landscape fire smoke, and emergency ambulance dispatches in Sydney. Australia. Environ Int 2017; 99: 208–212.
  • 11. Borchers Arriagada N, Horsley JA, Palmer AJ, et al. Association between fire smoke fine particulate matter and asthma‐related outcomes: Systematic review and meta‐analysis. Environ Res 2019; 179: 108777.
  • 12. Shaposhnikov BD, Revich BB, Bellander BT, et al. Mortality related to air pollution with the Moscow heat wave and wildfire of 2010. Epidemiology 2014; 25: 359–364.
  • 13. Holstius DM, Reid CE, Jesdale BM, et al. Birth weight following pregnancy during the 2003 Southern California wildfires. Environ Health Perspect 2012; 120: 1340–1345.
  • 14. Melody SM, Ford JB, Wills K, et al. Maternal exposure to fine particulate matter from a large coal mine fire is associated with gestational diabetes mellitus: a prospective cohort study. Environ Res 2019; 108956 [Epub ahead of print].
  • 15. World Health Organization Europe. Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide. Global update 2005. Copenhagen: WHO, 2006. http://www.euro.who.int/__data/assets/pdf_file/0005/78638/E90038.pdf?ua=1 (viewed Jan 2020).
  • 16. Willoughby M, Kipsaina C, Ferrah N, et al. Mortality in nursing homes following emergency evacuation: a systematic review. J Am Med Dir Assoc 2017; 18: 664–670.
  • 17. Laumbach R, Meng Q, Kipen H. What can individuals do to reduce personal health risks from air pollution? J Thorac Dis 2015; 7: 96–107.
  • 18. Whyand T, Hurst JR, Beckles M, et al. Pollution and respiratory disease: can diet or supplements help? A review. Respir Res 2018; 19: 79.
  • 19. Lin Z, Chen R, Jiang Y, et al. Cardiovascular benefits of fish‐oil supplementation against fine particulate air pollution in China. J Am Coll Cardiol 2019; 73: 2076–2085.
  • 20. Cherrie JW, Apsley A, Cowie H, et al. Effectiveness of face masks used to protect Beijing residents against particulate air pollution. Occup Environ Med 2018; 75: 446–452.
  • 21. McDonald F, Horwell CJ, Wecker R, et al. Facemask use for community protection from air pollution disasters: An ethical overview and framework to guide agency decision making. Int J Disaster Risk Reduction 2020; 43: 101376.
  • 22. Huang W, Morawska L. Face masks could raise pollution risks. Nature 2019; 574: 29–30.
  • 23. Johnston HL, Mueller W, Steinle S, et al. How harmful is particulate matter emitted from biomass burning? A Thailand perspective Curr Pollut Rep 2019; 5: 353–377.
  • 24. Muller RA, Muller EA. Air pollution and cigarette equivalence. Berkeley Earth. http://berkeleyearth.org/air-pollution-and-cigarette-equivalence/ (viewed Jan 2020).
  • 25. Australian National University Research School of Population Health. How to protect yourself and others from bushfire smoke. https://rsph.anu.edu.au/news-events/news/how-protect-yourself-and-others-bushfire-smoke (viewed Jan 2020).
  • 26. Centre for Air pollution, energy and health Research. Bushfire smoke: what are the health impacts and what can we do to minimise exposure? 10 Dec 2019. https://www.car-cre.org.au/factsheets (viewed Jan 2020).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes

Renata Libianto, Timothy ME Davis and Elif I Ekinci
Med J Aust 2020; 212 (3): . || doi: 10.5694/mja2.50472
Published online: 17 February 2020

Summary

  • Treatment options for type 2 diabetes have expanded. While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.
  • SGLT2 inhibitors are recommended for people with atherosclerotic cardiovascular disease, heart failure or kidney disease. Diabetic ketoacidosis is an uncommon but important side effect; its occurrence can be minimised with appropriate patient education and management, especially during perioperative periods and times of illness.
  • GLP1 receptor agonists are recommended for people with atherosclerotic cardiovascular disease. Gastrointestinal side effects are common but are less prominent with the longer acting agents and can be minimised with slow titration of the shorter acting agents.
  • DPP4 inhibitors are generally well tolerated, but alogliptin and saxagliptin should be used with caution in people with risk factors for heart failure.
  • To optimise the management of type 2 diabetes, clinicians need to be aware of the pharmacological characteristics of each class of blood glucose‐lowering medications and of the effect on cardiovascular health and renal function, balanced by potential adverse effects.
  • Medications that have cardiovascular or renal benefits should be prescribed for patients with these comorbidities, and this is reflected in recent international guidelines.

  • 1 Melbourne University, Melbourne, VIC
  • 2 University of Western Australia, Perth, WA
  • 3 Austin Health, Melbourne, VIC


Correspondence: elif.ekinci@unimelb.edu.au

Acknowledgements: 

Renata Libianto is supported by a National Health and Medical Research Council/National Heart Foundation of Australia postgraduate scholarship and by the Royal Australasian College of Physicians (RACP). Timothy Davis is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Practitioner Fellowship. Elif Ekinci has received grant funding from Viertel, RACP, Sir Edward Weary Dunlop Medical Research Foundation, and Diabetes Australia Research Program.

Competing interests:

Elif Ekinci's institute has received research funding from Novo Nordisk, Sanofi, GeNeuro and Dimerix. Timothy Davis has served on advisory boards for, and received research funding, speaker fees and travel assistance to attend meetings from, Merck Sharp and Dohme (manufacturer of sitagliptin and ertugliflozin), NovoNordisk (manufacturer of liraglutide and semaglutide), and Eli Lilly (manufacturer of dulaglutide). He has also served on advisory boards for, and received speaker fees and travel assistance to attend meetings from, AstraZeneca (manufacturer of saxagliptin, exenatide and dapagliflozin) and Boehringer Ingelheim (manufacturer of linagliptin and empagliflozin).

  • 1. Australian Bureau of Statistics. National Health Survey: first results, 2017–18 [Cat. No. 4364.0.55.001]. http://www.abs.gov.au/ausstats/abs@.nsf/PrimaryMainFeatures/4364.0.55.001?OpenDocument (viewed May 2019).
  • 2. Davis WA, Peters KE, Makepeace A, et al. Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II. Intern Med J 2018; 48: 803–809.
  • 3. Lee CM, Colagiuri R, Magliano DJ, et al. The cost of diabetes in adults in Australia. Diabetes Res Clin Pract 2013; 99: 385–390.
  • 4. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256–263.
  • 5. Komajda M, McMurray JJ, Beck‐Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824–831.
  • 6. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre‐diabetes and type 2 diabetes: a systematic review and meta‐analysis. BMJ Open 2017; 7: e013927.
  • 7. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–2498.
  • 8. Australian Diabetes Society. Australian type 2 diabetes management algorithm. ADS, 2020. http://t2d.diabetessociety.com.au/documents/4tuVr56d.pdf (viewed Dec 2019).
  • 9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.
  • 10. Food and Drug Administration. Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. FDA, 2008. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf (viewed May 2019).
  • 11. Zinman B, Wanner C, Lachin JM, et al. EMPA‐REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 Nov; 373: 2117–2128.
  • 12. Abdul‐Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA‐REG OUTCOME study. Diabetes Care 2016; 39: 717–725.
  • 13. Verma S, Rawat S, Ho KL, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci 2018; 3: 575–587.
  • 14. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
  • 15. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357.
  • 16. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. The N Engl J Med 2016; 375: 323–334.
  • 17. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295–2306.
  • 18. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376: 2300–2302.
  • 19. Tang H, Li D, Wang T, et al. Effect of sodium‐glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta‐analysis of randomized controlled trials. Diabetes Care 2016; 39: e123–e124.
  • 20. Vellanki P, Umpierrez GE. Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. Endocr Pract 2017; 23: 971–978.
  • 21. Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 2019; 104: 3077–3087.
  • 22. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849–2852.
  • 23. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638–1642.
  • 24. Australian Diabetes Society. Alert: severe euglycaemic ketoacidosis with SGLT2 inhibitor use in the perioperative period. https://diabetessociety.com.au/documents/2018_ALERT-ADS_SGLT2i_PerioperativeKetoacidosis_v3__final2018_02_14.pdf (viewed May 2019).
  • 25. Food and Drug Administration. Highlights of prescribing information. FDA, 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s015s019lbl.pdf (viewed Nov 2019).
  • 26. Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity‐matched analysis. Diabetes Care 2017; 40: 1479–1485.
  • 27. Sung J, Padmanabhan S, Gurung S, et al. SGLT2 inhibitors and amputation risk: real‐world data from a diabetes foot wound clinic. J Clin Transl Endocrinol 2018; 13: 46–47.
  • 28. Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.
  • 29. Marso SP, Bain SC, Consoli A, et al. SUSTAIN‐6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844.
  • 30. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double‐blind, randomised placebo‐controlled trial. Lancet 2018; 392: 1519–1529.
  • 31. Gerstein HC, Coulhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‐blind, randomised placebo‐controlled trial. Lancet 2019; 394: 121–130.
  • 32. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once‐weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228–1239.
  • 33. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–2257.
  • 34. Sun F, Wu S, Guo S, et al. Impact of GLP‐1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta‐analysis. Diabetes Res Clin Pract 2015; 110: 26–37.
  • 35. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014; 64: 731–737.
  • 36. Lovshin JA, Barnie A, DeAlmeida A, et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015; 38: 132–139.
  • 37. Del Olmo‐Garcia MI, Merino‐Torres JF. GLP‐1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res 2018; 2018: 4020492.
  • 38. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta‐analysis. BMJ Open 2013; 3: e001986.
  • 39. Drucker DJ. Mechanisms of action and therapeutic application of glucagon‐like peptide‐1. Cell Metab 2018; 27: 740–756.
  • 40. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7): a multicentre, open‐label, randomised trial. Lancet Diabetes Endocrinol 2018; 6: 605–617.
  • 41. Mann JFE, Orsted DD, Brown‐Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839–848.
  • 42. Shyangdan DS, Royle P, Clar C, et al. Glucagon‐like peptide analogues for type 2 diabetes mellitus. Cochrane Database System Rev 2011; (10): CD006423.
  • 43. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1‐based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population‐based matched case‐control study. JAMA Intern Med 2013; 173: 534–539.
  • 44. Storgaard H, Cold F, Gluud LL, et al. Glucagon‐like peptide‐1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19: 906–908.
  • 45. Home P. Cardiovascular outcome trials of glucose‐lowering medications: an update. Diabetologia 2019; 62: 357–369.
  • 46. Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018; 20: 889–897.
  • 47. Feldman‐Billard S, Larger É, Massin P. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab 2018; 44: 4–14.
  • 48. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242.
  • 49. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.
  • 50. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
  • 51. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019; 321: 69–79.
  • 52. Food and Drug Administration. FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin 2014. https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm (viewed May 2019).
  • 53. Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf 2014; 5: 138–146.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Pagination

Subscribe to